Automated Isolation of Peripheral Blood Mononuclear Cells Using the PBMC Accumulator System
First written in FY2024. 1 of 2 entries say "Restated". Latest entry: FY2026.
No other company in this theme has enough history to compare yet.
- FY2026RestatedAnnual report
「Through joint research, we are pursuing the development and expanded application of new technologies, including the joint research project with Kyoto University and ユニバーサル・バイオ・リサーチ株式会社, “Development of an automated device for separating peripheral blood PBMCs* and target cells,” further evaluation of the utility of the fully automated gene testing device geneLEAD series, and regulatory applications for newly applicable in vitro diagnostic items.」
The policy of pursuing, through joint research, the automated separation of PBMCs and target cells, evaluation of the utility of geneLEAD, and regulatory applications for new in vitro diagnostic items remains in place. - FY2024First statedAnnual report
「PBMC refers to Peripheral Blood Mononuclear Cells, or human peripheral blood mononuclear cells. We aim to develop a device equipped with our proprietary “electrode chip” technology that can automatically and efficiently separate PBMCs, which form the foundation of immunological research into diseases.」
A new priority development theme was identified for the first time, aiming to develop a device that automatically separates PBMCs using electrode chip technology.